Andrea Granados
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andrea Granados has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Amir Moheet
Department of Medicine, University of Minnesota, Minneapolis, MN, USA
4 shared publications - Christine L. Chan
Pediatric Endocrinology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, 13123 East 16th Avenue, B265, Aurora, CO 80045, USA
4 shared publications Antoinette Moran
Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA
3 shared publicationsKatie Larson Ode
Department of Pediatrics, University of Iowa Stead Family Children's Hospital, Iowa City, IA, USA
2 shared publicationsAlberto Battezzati
International Center for the Assessment of Nutritional Status (ICANS), Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, Milan, Italy
1 shared publicationAmanda L. Brennan
Manchester Adult Cystic Fibrosis Center, University Hospital South Manchester, Wythenshawe, Manchester, UK
1 shared publication
Latest Publications
- 14 March 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 755-758
Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor
- 14 March 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 755-758
Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor
- Open Access
- 1 October 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S19-S24
Hypoglycemia in cystic fibrosis: Prevalence, impact and treatment
- 1 October 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S19-S24
Open AccessHypoglycemia in cystic fibrosis: Prevalence, impact and treatment
- Open Access
- 1 October 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S10-S18
Cystic fibrosis related diabetes: Medical management
- 1 October 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S10-S18
Open AccessCystic fibrosis related diabetes: Medical management
- Open Access
- 1 October 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S3-S9
Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis
- 1 October 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S3-S9
Open AccessCystic fibrosis related diabetes: Pathophysiology, screening and diagnosis
- Open Access
- 15 May 2017
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 175 (2) , 253-259
MAP3K1‐related gonadal dysgenesis: Six new cases and review of the literature
Investigation of disorders of sex development (DSD) has resulted in the discovery of multiple sex‐determining genes. MAP3K1 encodes a signal transduction regulator in the sex determination pathway and is emerging as one of the more common genes responsible for 46,XY DSD presenting as complete or partial gonadal dysgenesis. Clinical assessment, endocrine evaluation, and genetic analysis were performed in six individuals from four unrelated families with 46,XY DSD. All six individuals were found to have likely pathogenic MAP3K1 variants. Three of these individuals presented with complete gonadal dysgenesis, characterized by bilateral streak gonads with typical internal and external female genitalia, while the other three presented with partial gonadal dysgenesis, characterized by incomplete testicular development, resulting in clitoral hypertrophy with otherwise typical female external genitalia. Testing for MAP3K1 variants should be considered in patients with 46,XY complete or partial gonadal dysgenesis, particularly in families with multiple members affected with 46,XY DSD. Identification of a MAP3K1 variant should prompt an evaluation for DSD in female siblings of the proband.
- 15 May 2017
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 175 (2) , 253-259
Open AccessMAP3K1‐related gonadal dysgenesis: Six new cases and review of the literature
Investigation of disorders of sex development (DSD) has resulted in the discovery of multiple sex‐determining genes. MAP3K1 encodes a signal transduction regulator in the sex determination pathway and is emerging as one of the more common genes responsible for 46,XY DSD presenting as complete or partial gonadal dysgenesis. Clinical assessment, endocrine evaluation, and genetic analysis were performed in six individuals from four unrelated families with 46,XY DSD. All six individuals were found to have likely pathogenic MAP3K1 variants. Three of these individuals presented with complete gonadal dysgenesis, characterized by bilateral streak gonads with typical internal and external female genitalia, while the other three presented with partial gonadal dysgenesis, characterized by incomplete testicular development, resulting in clitoral hypertrophy with otherwise typical female external genitalia. Testing for MAP3K1 variants should be considered in patients with 46,XY complete or partial gonadal dysgenesis, particularly in families with multiple members affected with 46,XY DSD. Identification of a MAP3K1 variant should prompt an evaluation for DSD in female siblings of the proband.